Our Programmes


When COVID-19 entered the world stage in late 2019, it was clear that this virus could cause severe lung illness. Many people were becoming so breathless they required hospitalisation, supplemental oxygen and ventilation. Human lungs were not coping as they should with this virus.

Image courtesy of the National Institute of Allergy and Infectious Diseases

Our team started asking questions about the role inhaled IFN-β might play in helping the respiratory system behave in the way it is designed to. By delivering IFN-β directly to the lungs through inhalation, could it be successful in switching on the body’s natural defences to clear the virus? By March 2020, we had initiated a placebo-controlled Phase 2 trial in COVID-19 patients in the UK. And by January 2021, our Phase 3 trial which would ultimately include 17 countries, had begun.

SNG001 is also being investigated independently as part of the US National Institute of Health’s ACTIV programme to accelerate the development of the most promising COVID-19 treatments. The ACTIV-2 study (ClinicalTrials.gov Identifier: NCT04518410), sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and led by the NIAID-funded AIDS Clinical Trials Group (ACTG), is testing agents in outpatient adults with documented positive SARS-CoV-2 infection and symptoms of COVID-19. The Phase 3 element of this trial, to which SNG001 has graduated, is recruiting only outpatients at higher risk of progression to hospitalisation or death. Learn more about ACTIV-2 here.


Phase 3 double-blind, placebo-controlled, trial of inhaled IFN-beta, SNG001, in hospitalised COVID-19 patients

​Read more about SG018 at clinicaltrials.gov

Synairgen reported topline results of SPRINTER (SG018) in February 2022. You can read the press release here.

SG016 Trial

Phase 2 double-blind, placebo-controlled trial of inhaled IFN-beta, SNG001, in hospitalised COVID-19 patients

Read more about SG016 at clinicaltrials.gov

Access the results of SG016 in the Lancet Respiratory Medicine.

SG019 Trial

Pilot Test of Clinical Outcome Assessment Methodology and Qualitative Evidence of Content Validity

This is a pilot trial requested by regulators to validate the additional questions that are included in SG018 which determine the OSCI score when patients have been discharged from hospital. The study is proceeding on time and as it is an independent study, will not delay the SPRINTER study (SG018).

Read more about SG019 at clinicaltrials.gov